135 related articles for article (PubMed ID: 8931947)
1. Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent.
Takesada H; Matsuda K; Ohtake R; Mihara R; Ono I; Tanaka K; Naito M; Yatagai M; Suzuki E
Bioorg Med Chem; 1996 Oct; 4(10):1771-81. PubMed ID: 8931947
[TBL] [Abstract][Full Text] [Related]
2. Determination of N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and its metabolites in human plasma and urine by column-switching high-performance liquid chromatography with ultraviolet detection.
Ono I; Matsuda K; Kanno S
J Chromatogr B Biomed Sci Appl; 1997 May; 692(2):397-404. PubMed ID: 9188829
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus.
Tamura M; Shiba S; Kudo N; Kawashima Y
Chirality; 2010 Jan; 22(1):92-8. PubMed ID: 19387990
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats.
Jin L; Baillie TA
Chem Res Toxicol; 1997 Mar; 10(3):318-27. PubMed ID: 9084912
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of pantoprazole involving conjugation with glutathione in rats.
Zhong D; Xie Z; Chen X
J Pharm Pharmacol; 2005 Mar; 57(3):341-9. PubMed ID: 15807990
[TBL] [Abstract][Full Text] [Related]
6. Structure determination of biliary metabolites of schizandrin in rat and dog.
Ikeya Y; Sugama K; Tanaka M; Wakamatsu T; Ono H; Takeda S; Oyama T; Maruno M
Chem Pharm Bull (Tokyo); 1995 Jan; 43(1):121-9. PubMed ID: 7895304
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Inoue T; Shibahara N; Miyagawa K; Itahana R; Izumi M; Nakanishi T; Takamitsu Y
Clin Nephrol; 2003 Aug; 60(2):90-5. PubMed ID: 12940610
[TBL] [Abstract][Full Text] [Related]
8. Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR.
Mutlib AE; Shockcor J; Chen SY; Espina RJ; Pinto DJ; Orwat MJ; Prakash SR; Gan LS
Chem Res Toxicol; 2002 Jan; 15(1):48-62. PubMed ID: 11800597
[TBL] [Abstract][Full Text] [Related]
9. N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2.
Shinkai H; Nishikawa M; Sato Y; Toi K; Kumashiro I; Seto Y; Fukuma M; Dan K; Toyoshima S
J Med Chem; 1989 Jul; 32(7):1436-41. PubMed ID: 2738878
[TBL] [Abstract][Full Text] [Related]
10. [Clinical trial of AY4166].
Kikuchi M
Nihon Rinsho; 1997 Nov; 55 Suppl():164-70. PubMed ID: 9434462
[No Abstract] [Full Text] [Related]
11. Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2.
Terada T; Sawada K; Saito H; Hashimoto Y; Inui K
Eur J Pharmacol; 2000 Mar; 392(1-2):11-7. PubMed ID: 10748266
[TBL] [Abstract][Full Text] [Related]
12. Identification of the metabolites of roxithromycin in humans.
Zhong D; Li X; Wang A; Xu Y; Wu S
Drug Metab Dispos; 2000 May; 28(5):552-9. PubMed ID: 10772634
[TBL] [Abstract][Full Text] [Related]
13. Disposition and metabolism of the hypoglycemic agent pioglitazone in rats.
Krieter PA; Colletti AE; Doss GA; Miller RR
Drug Metab Dispos; 1994; 22(4):625-30. PubMed ID: 7956739
[TBL] [Abstract][Full Text] [Related]
14. Metabolic studies of mesterolone in horses.
Ho EN; Leung DK; Leung GN; Wan TS; Wong HN; Xu X; Yeung JH
Anal Chim Acta; 2007 Jul; 596(1):149-55. PubMed ID: 17616252
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism.
Wu WN; McKown LA; Reitz AB
Eur J Drug Metab Pharmacokinet; 2006; 31(4):277-83. PubMed ID: 17315539
[TBL] [Abstract][Full Text] [Related]
16. Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs.
Makino C; Sakai H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):907-13. PubMed ID: 19721250
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial antigens and autoantibodies: from anti-M1 to anti-M9.
Berg PA; Klein R
Klin Wochenschr; 1986 Oct; 64(19):897-909. PubMed ID: 3537495
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of nateglinide in humans.
Weaver ML; Orwig BA; Rodriguez LC; Graham ED; Chin JA; Shapiro MJ; McLeod JF; Mangold JB
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):415-21. PubMed ID: 11259325
[TBL] [Abstract][Full Text] [Related]
19. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
Karara AH; Dunning BE; McLeod JF
J Clin Pharmacol; 1999 Feb; 39(2):172-9. PubMed ID: 11563410
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of [6]-shogaol in mice and in cancer cells.
Chen H; Lv L; Soroka D; Warin RF; Parks TA; Hu Y; Zhu Y; Chen X; Sang S
Drug Metab Dispos; 2012 Apr; 40(4):742-53. PubMed ID: 22246389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
